Directing transition from innate to acquired immunity defining a role for IL-6

被引:601
作者
Jones, SA [1 ]
机构
[1] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, Wales
基金
英国惠康基金;
关键词
D O I
10.4049/jimmunol.175.6.3463
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Appropriate control of leukocyte recruitment and activation is a fundamental requirement for competent host defense and resolving inflammation. A pivotalevent that defines the successful outcome of any inflammatory event is the transition from innate to acquired immunity. In IL-6 deficiency, this process appears defective, and a series of in vivo studies have documented important roles for IL-6 in both the resolution of innate immunity and the development of acquired immune responses. Within this review, particular attention will be given to the regulatory properties of the soluble IL-6 receptor and how its activity may affect chronic disease progression.
引用
收藏
页码:3463 / 3468
页数:6
相关论文
共 71 条
[1]   Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo [J].
Atreya, R ;
Mudter, J ;
Finotto, S ;
Müllberg, J ;
Jostock, T ;
Wirtz, S ;
Schütz, M ;
Bartsch, B ;
Holtmann, M ;
Becker, C ;
Strand, D ;
Czaja, J ;
Schlaak, JF ;
Lehr, HA ;
Autschbach, F ;
Schürmann, G ;
Nishimoto, N ;
Yoshizaki, K ;
Ito, H ;
Kishimoto, T ;
Galle, PR ;
Rose-John, S ;
Neurath, MF .
NATURE MEDICINE, 2000, 6 (05) :583-588
[2]   A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis [J].
Atsumi, T ;
Ishihara, K ;
Kamimura, D ;
Ikushima, H ;
Ohtani, T ;
Hirota, S ;
Kobayashi, H ;
Park, SJ ;
Saeki, Y ;
Kitamura, Y ;
Hirano, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (07) :979-990
[3]   PROTECTIVE ROLE OF INTERLEUKIN-6 IN THE LIPOPOLYSACCHARIDE-GALACTOSAMINE SEPTIC SHOCK MODEL [J].
BARTON, BE ;
JACKSON, JV .
INFECTION AND IMMUNITY, 1993, 61 (04) :1496-1499
[4]   TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling [J].
Becker, C ;
Fantini, MC ;
Schramm, C ;
Lehr, HA ;
Wirtz, S ;
Nikolaev, A ;
Burg, J ;
Strand, S ;
Kiesslich, R ;
Huber, S ;
Ito, H ;
Nishimoto, N ;
Yoshizaki, K ;
Nishimoto, N ;
Galle, PR ;
Blessing, M ;
Rose-John, S ;
Neurath, MF .
IMMUNITY, 2004, 21 (04) :491-501
[5]   Increased and long-term generation of dendritic cells with reduced function from IL-6-deficient bone marrow [J].
Bleier, JI ;
Pillarisetty, VG ;
Shah, AB ;
DeMatteo, RP .
JOURNAL OF IMMUNOLOGY, 2004, 172 (12) :7408-7416
[6]  
Chen CK, 2004, ASIAN J CONTROL, V6, P130, DOI 10.1111/j.1934-6093.2004.tb00191.x
[7]   IL-6 switches the differentiation of monocytes from dendritic cells to macrophages [J].
Chomarat, P ;
Banchereau, J ;
Davoust, J ;
Palucka, AK .
NATURE IMMUNOLOGY, 2000, 1 (06) :510-514
[8]   Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].
Choy, EHS ;
Isenberg, DA ;
Garrood, T ;
Farrow, S ;
Ioannou, Y ;
Bird, H ;
Cheung, N ;
Williams, B ;
Hazleman, B ;
Price, R ;
Yoshizaki, K ;
Nishimoto, N ;
Kishimoto, T ;
Panayi, GS .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150
[9]   Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling [J].
Curnow, SJ ;
Scheel-Toellner, D ;
Jenkinson, W ;
Raza, K ;
Durrani, OM ;
Faint, JM ;
Rauz, S ;
Wloka, K ;
Pilling, D ;
Rose-John, S ;
Buckley, CD ;
Murray, PI ;
Salmon, M .
JOURNAL OF IMMUNOLOGY, 2004, 173 (08) :5290-5297
[10]  
Desgeorges A, 1997, J RHEUMATOL, V24, P1510